Cardlytics Announces Sale of Bridg Platform to PAR Technology: Key Investor Insights

Overview of the Transaction

Cardlytics, Inc. has disclosed that it entered into an asset purchase agreement with PAR Technology Corporation and its subsidiary, D LLC, on January 23, 2026. Under this agreement, Cardlytics will sell all assets, properties, and rights primarily related to its Bridg platform, subject to certain exceptions. This is a significant corporate action and marks a major shift in Cardlytics’ business model, as Bridg was a core platform offering.

Financial Impact and Pro Forma Statements

The company has provided unaudited pro forma condensed consolidated financial statements to illustrate the impact of the transaction. These statements reflect the company’s financial position as if the transaction had taken place on December 31, 2025, and show the results of operations as if the sale occurred on January 1, 2023. The Bridg business is now classified as discontinued operations in all periods presented.

Balance Sheet Highlights

• Assets: Cardlytics’ cash and cash equivalents remain unchanged at \$48.7 million post-transaction, while marketable securities increase by \$25.4 million, reflecting the stock received from the Buyer.
• Reduction of Bridg-related Assets: Intangible assets, capitalized software development costs, and other long-term assets associated with Bridg are removed, reducing total assets related to discontinued operations.
• Net Gain: A preliminary estimated gain of \$13.9 million is recognized, calculated as the \$25.4 million consideration less \$1.6 million transaction costs and Bridg net assets of \$9.9 million.
• Equity Improvement: The transaction eliminates accumulated deficits associated with Bridg and boosts the company’s stockholders’ equity from a deficit of \$6.5 million to a positive \$7.4 million post-transaction.

Statement of Operations Highlights

• Revenue: Pro forma revenues for 2025, 2024, and 2023 are significantly lower following the removal of Bridg-related revenues (\$20.9M for 2025, \$22.7M for 2024, \$23.8M for 2023).
• Operating Losses Narrow: Operating losses decrease notably after excluding Bridg, with pro forma net losses per share improving (e.g., from \$(1.95) to \$(1.72) in 2025).
• Cost Structure: Significant reductions in delivery, sales & marketing, and R&D expenses, as Bridg-related costs are eliminated.
• Impairments: Substantial impairment charges related to goodwill and intangible assets were previously recorded, indicating that Bridg was underperforming and its sale may have been a strategic pivot.

Shareholder-Relevant and Price Sensitive Information

• Significant Corporate Event: The sale of Bridg constitutes a “significant disposition” under SEC rules, which is likely to impact investor perception and the company’s valuation.
• Cash and Liquidity: Receipt of \$25.4 million in stock from the Buyer materially increases Cardlytics’ liquidity and strengthens its balance sheet.
• Discontinued Operations: Bridg is now classified as discontinued operations, and its historical losses no longer burden Cardlytics’ ongoing business results.
• No Synergies Reflected: The pro forma statements do not reflect any potential cost savings, synergies, or dis-synergies following the transaction. Actual future results may differ from pro forma estimates.
• Potential for Share Price Movement: The transaction removes a loss-making segment, improves equity, and provides new liquidity, all of which can be positive for share price. However, the loss of revenue from Bridg may also affect future growth prospects.

Key Notes and Cautions for Investors

• Estimates Subject to Change: The gain on sale and final accounting will depend on actual transaction closing figures and may differ from current estimates.
• Regulatory Presentation: The pro forma financials have been prepared in accordance with Article 11 of Regulation S-X and are for illustrative purposes only. They do not necessarily reflect future actual results.
• Quarterly Reporting: Final discontinued operations accounting will be updated in forthcoming quarterly and annual filings for 2026.

Conclusion

The sale of the Bridg platform marks a pivotal moment for Cardlytics. The transaction improves the company’s liquidity, reduces operating losses, and strengthens its equity position. While it removes a loss-making segment, it also reduces total revenues and could affect future growth trajectories. Investors should monitor forthcoming financial disclosures for updated figures and consider both the immediate financial benefits and the strategic implications for Cardlytics’ core business.

Disclaimer: This article is based on unaudited pro forma financial statements and preliminary management estimates. Actual results may differ. Investors should consult official SEC filings and seek professional advice before making investment decisions. This article does not constitute investment advice or a recommendation to buy or sell Cardlytics shares.

View Cardlytics, Inc. Historical chart here